Dendreon Corporation (NASDAQ: DNDN) is surging on news that the Centers for Medicare and Medicaid Services will now cover the infusion costs associated with the administration of PROVENGE. Dendreon noted that this new coverage of PROVENGE is now consistent with all other infused biologics.
The costs associated with administering PROVENGE will now be covered and can be billed separately. More importantly, the CMS decision will retroactively cover claims for costs associated with the administration of PROVENGE effective for dates on or after June 30, 2011. This now takes the average time to pay physicians to 30 days according to the company.
Dendreon shares are up over 8% at $9.03 in pre-market trading with about 55 minutes until the market opens and the 52-week trading range is $6.46 to $43.96.
JON C. OGG
Smart Investors Are Quietly Loading Up on These “Dividend Legends”
If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.
Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
